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Abstract: Angiogenesis is considered integral to the reparative process after ischemic injury. The αvβ3
integrin is a critical modulator of angiogenesis and highly expressed in activated endothelial cells.
68Ga-NODAGA-E[(cRGDyK)]2 (RGD) is a positron-emission-tomography (PET) ligand targeted
towards αvβ3 integrin. The aim was to present data for the uptake of RGD and correlate it with
histology and to further illustrate the differences in angiogenesis due to porcine adipose-derived
mesenchymal stromal cell (pASC) or saline treatment in minipigs after induction of myocardial
infarction (MI). Three minipigs were treated with direct intra-myocardial injection of pASCs and
two minipigs with saline. MI was confirmed by 82Rubidium (82Rb) dipyridamole stress PET.
Mean Standardized Uptake Values (SUVmean) of RGD were higher in the infarct compared to
non-infarct area one week and one month after MI in both pASC-treated (SUVmean: 1.23 vs. 0.88 and
1.02 vs. 0.86, p < 0.05 for both) and non-pASC-treated minipigs (SUVmean: 1.44 vs. 1.07 and 1.26
vs. 1.04, p < 0.05 for both). However, there was no difference in RGD uptake, ejection fractions,
coronary flow reserves or capillary density in histology between the two groups. In summary,
indications of angiogenesis were present in the infarcted myocardium. However, no differences
between pASC-treated and non-pASC-treated minipigs could be demonstrated.
Keywords: myocardial perfusion; RGD; rubidium; cardiac positron-emission-tomography; angiogenesis;
mesenchymal stromal cells; hydrogel; stem cell; myocardial infarction
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1. Introduction
The formation of new capillaries or angiogenesis, is considered a vital part of the natural
recovery after an ischemic injury and is, therefore, a key factor for post-ischemic repair of the
infarcted myocardium [1]. Since angiogenesis is associated with post-infarct remodeling of the left
ventricle, and thus prognosis following myocardial infarction, it is of particular interest to be able
to noninvasively monitor angiogenesis [2,3]. This might not only permit for a risk stratification of
patients following myocardial infarction, but also facilitate development and improvement of new
therapies directed towards stimulation of the natural angiogenic response.
Myocardial angiogenesis following myocardial infarction might be focal or non-transmural
making it difficult to detect noninvasively, and existing noninvasive imaging methods directed towards
the evaluation of angiogenesis have been somewhat limited.
During angiogenesis, endothelial cells must adhere to one another and to the extracellular matrix
in order to form new microvessels and to extend existing ones [4,5]. The cross-talk with the extracellular
matrix is mediated by integrins, which are a family of heterodimeric cell surface receptors involved in many
cellular processes, including adhesion, migration, proliferation, and survival [6]. Specifically, the αvβ3
integrin has been identified as a critical modulator of angiogenesis. It is highly expressed in activated
endothelial cells, and therefore serves as a potential target for directly imaging angiogenesis [5,7–9].
The aim of this study was to present data for the uptake of a newly developed
angiogenesis positron-emission-tomography (PET) tracer targeted towards αvβ3 integrin
(68Ga-NODAGA-E[c(RGDyK)]2 (RGD)) [7] and correlate it with histology and further to illustrate the
differences in angiogenesis in Göttingen minipigs treated with saline or porcine adipose-derived
mesenchymal stromal cell (pASC) suspended in alginate hydrogel after induction of acute
myocardial infarction.
2. Materials and Methods
2.1. Study Design
Five Göttingen minipigs were used in this study. The study was approved by The National
Committee for the Protection of Animals used for Scientific Purposes in Denmark (1 July 2014,
Authorization number 2014-15-0201-00191). The infarction model was an acute model of myocardial
infarction with permanent ligation and pASC or saline treatment immediately after the infarct induction.
The minipigs underwent PET-imaging examining myocardial perfusion (82Rubidium(82Rb)-PET) and
neo-angiogenesis (68Ga-NODAGA-RGD) at baseline and one week and four weeks after infarct induction
and treatment (Figure 1).
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Tomography; MI: Myocardial infarction; pASC: porcine adipose-derived mesenchymal stromal cell.
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2.2. Preparation for Scans
The minipigs were sedated with an intramuscular injection of 0.08 or 0.1 mL/kg (before and after
an induced myocardial infarction) of a mixture of zolezapam 10.9 mg/mL and tiletamine 10.9 mg/mL
(Zoletil 50/50® vet; Virbac, Carros, France), xylazine 10.9 mg/mL (Xysol vet; ScanVet Animal Health
A/S, Fredensborg, Denmark), ketamine 10.9 mg/mL (Ketaminol vet, Intervet International B.V.,
Boxmeer, the Netherlands), methadone 1.7 mg/mL (Comfortan vet, Dechra Veterinary Products
A/S, Uldum, Denmark) and butorphanol 1.7 mg/mL (Torbugesic vet, ScanVet Animal Health A/S,
Fredensborg, Denmark). When in lateral recumbency minipigs were moved to the preparation room
for instrumentation. For each scan minipigs were instrumented with 3 intravenous accesses (one in
each ear (lateral auricular vene) and one in the hind leg (branch of v. saphena)) for anesthesia and PET
tracer administration, a urinary bladder catheter, and a tracheal tube for ventilation. During anesthesia
saturation (SpO2), ECG, non-invasive blood pressure, temperature and end-tidal CO2 were monitored
using a Datex-Ohmeda S/5 compact monitor (GE Healthcare, Brøndbyvester, Denmark). When fully
instrumented the minipigs were transported to the scanner and put on respirator. Respiration was
set to obtain normo ventilation with an end-tidal CO2 of approximately 55 cmH2O. Minipigs were
kept anesthetized with a maintenance dose of intravenous propofol 10 mg/kg/h during the 82Rb-PET
computed tomography (CT) (Siemens mCT, Siemens, 128-slice CT, Knoxville, TN, USA).
2.3. Infarct Induction and Stromal Cell Treatment
2.3.1. Göttingen Minipig Adipose-Derived Mesenchymal Stromal Cells
Abdominal subcutaneous adipose tissue was harvested from recently euthanized Göttingen
minipigs. The tissue was manually cut from the abdominal region and stored in phosphate-buffered
saline (PBS) pH 7.4 (Gibco, Life Technologies, Carlsbad, CA, USA) with 5% penicillin/streptomycin
for transportation. The tissue was manually cut into small pieces before being processed as with
human samples. The pieces were treated with 0.6 PZ U/mL collagenase NB4 (SERVA Electrophoresis)
dissolved in Hank’s buffered saline solution (Gibco, diluted to a concentration of 2 mM Ca2+) for
one hour at 37 ◦C. The solution was filtered through a 100 µm filter (Cell Strainer, BD Falcon) and
washed trice with PBS. The resulting cells were seeded in T75 flasks in a density of 4.5 × 106 cells/flask
in complete medium (alpha-MEM (Gibco, Life Technologies), 10% fetal bovine serum (FBS) (Gibco,
Life Technologies), 1% penicillin/streptomycin. The resulting stromal vascular fraction was incubated
in an incubator with 37 ◦C and 5% CO2 for 2–3 days after which suspension cells were removed by
washing with PBS, before continuing culture. This resulted in a homogeneous population of pASCs,
which were stored in liquid nitrogen at a density of 5 × 106 per mL in 5% DMSO (WAK-Chemie
Medical, Steinbach, Germany) in FBS. Two weeks before the operation the cells were thawed and
cultured in complete medium again. The pASCs used for treatment were in passage 4 or 5.
The cells were tested for mesenchymal stromal cell abilities by performing differentiation
towards adipogenic, osteogenic, and chondrogenic lineage using StemPro differentiation kit (Gibco,
Life Technologies) according to manufacturer’s protocol. Differentiation was verified by lipid droplets
stained with Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) for adipogenic lineage, calcium deposition
by Alizarin Red S for osteogenic lineage, and glycosaminoglycans by Alcian Blue 8GX (Sigma-Aldrich,
St. Louis, MO, USA) for chondrogenic lineage.
Three minipigs were treated with pASC suspended in alginate hydrogel and two minipigs
with saline.
2.3.2. Alginate Hydrogel
The injectable alginate hydrogel was cast using very low viscosity (5cP) high guluronic acid
content (G > 65%) alginate (VLVG, NovaMatrix, FMC Biopolymers, Drammen, Norway) dissolved in
sterile water. The alginate solution was crosslinked using D-gluconic acid hemi calcium (Sigma-Aldrich,
St. Louis, MO, USA) yielding a free-flow injectable alginate hydrogel consisting of 1.5% (w/v) alginate
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and 0.9% (w/v) calcium ions, which was filtered through a 20 µm filter [10]. Centrifuged pASCs were
re-suspended in the alginate hydrogel and transferred to a sterile syringe prior to the operation.
2.3.3. Myocardial Infarct Induction and Treatment
The minipigs were sedated, instrumented, ventilated and monitored like described above
and kept anaesthetized on propofol (Propofol “B. Braun”; 10 mg/mL; B. Braun Medical A/S,
Frederiksberg, Denmark) with a dose range of 10–15 mg/kg/h depending on the individual response
to anesthesia. Fentanyl 0.5 µg/kg/h (Fentanyl “Hameln”; 50 µg/mL; Hameln Pharmaceuticals
Gmbh, Hameln, Germany) was given as infusion as intraoperative analgesic. Amoxicillin 15 mg/kg
(Curamox Prolongatum Vet.; 150 mg/mL; Boehringer Ingelheim DK A/S, Kalundborg, Denmark)
and meloxicam 0.4 mg/kg (Boehringer Ingelheim DK A/S, Denmark) were given prophylactic before
operation. Before surgical incision 50 mg of amiodaronhydrochlorid was administered intravenously
as a bolus. The heart was accessed through partial lower median sternotomy. A sternal retractor
was inserted, and the pericardium was opened with a scissor. The left anterior descending artery
and a large diagonal branch were identified. Myocardial infarction was induced by ligation with
a 5-0 prolene suture of the apical part of the LAD artery or a large diagonal artery (D2). After ligation
of the artery, a sharp demarcation line between ischemic and non-ischemic myocardium was observed.
Depending on the treatment arm, either isotonic saline or pASCs in alginate hydrogel was injected in
4–6 injections with a 25 G needle in the peri-infarct area on one side of the infarction. The minipigs in
the treatment group received approximately 40 × 106 pASCs in 2.5 mL alginate hydrogel. Afterward,
the sternum was closed with PDS 0 suture, the fascia and subcutis with 0 vicryl, and the cutis with
a 4-0 monocryl intradermal suture. The minipigs were treated post-operative with butorphanole
0.2 mg/kg (Torbugesic vet 10 mg/mL, ScanVet Animal Health A/S, Denmark) and methadone
0.2 mg/kg (Comfortan vet 10 mg/mL, Dechra Veterinary Products A/S, Denmark) every 3–4 h for the
first 24 h. Subsequently, they were treated with buprenorfin 0.01–0.02 mg/kg (Vetergesic 0.3 mg/mL,
Orion Pharma Animal Health, Copenhagen, Denmark) every 8th hour in 2–3 days. The opioid regime
was supported by oral administration of meloxicam 0.4 mg/kg (metacam oral suspension 15 mg/mL,
Boehringer Ingelheim DK A/S) for 5 days post-operative. Antibiotic treatment with amoxicillin
20 mg/kg (Clamoxyl VET. 51%, Orion Pharma Animal Health, Denmark) was continued orally in
6 days post-operative.
2.4. Radiochemistry: 68Ga-NODAGA-E[c(RGDyK)]2 Synthesis
NODAGA-E[c(RGDyK)]2 acetate was obtained from ABX GmbH (Radeberg, Germany).
Gallium-68 (t1/2 = 68 min; Emax,β+ = 1.90 MeV (89%)) labelling of NODAGA-E[c(RGDyK)]2
acetate was performed using a Modular-Lab eazy module (Eckert & Ziegler, Berlin, Germany).
The 68Ge/68Ga generator (IGG100, Eckert & Ziegler) was eluted with 6 mL 0.1 M HCl. The eluate
was concentrated on a Bond Elut SCX cartridge and eluted with 600 µL 5 M NaCl/5.5 M HCl (41:1).
NODAGA-E[c(RGDyK)]2 (30 nmol) was labelled in 1000 µL 0.7 M NaOAc buffer pH 4.5 and 400 µL
50% EtOH at 60 ◦C for 400 s. The resulting 68Ga-NODAGA-E[c(RGDyK)]2 was formulated with saline
or phosphate buffer.
The radiochemical purity was more than 96% on HPLC, and the amount of unlabeled 68Ga in the
product was less than 1%, as demonstrated by radio–thin layer chromatography.
All reagents and cassettes were purchased from Eckert & Ziegler. For analysis, a high-performance
liquid chromatograph (Ultimate 3000; Dionex, Sunnyvale, CA, USA) was used with a 2.6-µm, 100-Å,
50 × 4.6 mm C18 Kinetex column (Phenomenex, Torrance, CA, USA). The mobile phases were:
eluent A: 10% MeCN in H2O with 0.1% trifluoroacetic acid; eluent B: 10% H2O in MeCN with 0.1%
trifluoroacetic acid.
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2.5. 82Rubidium and 68GA-NODAGA-RGD PET Imaging
82Rb rest and stress myocardial perfusion PET-CT were performed before induction of myocardial
infarction, one week and one month after infarction (Figure 1). The 68GA-NODAGA-RGD (RGD)
PET-CT was performed as a 10 min ECG-gated scan 45 min after administration of 100 MBq
RGD. The 82Rb rest and stress myocardial perfusion PET-CT has previously been described in
detail [11,12]. In brief, a 7 min dynamic PET myocardial perfusion rest scan under administration of
1000–1200 MBq 82Rb was performed. Subsequently, a 7 min dynamic dipyridamole stress PET scan
was performed. Dipyridamole (140 µg/kg/min) was given as a continuous intravenous infusion over
4 min prior to 82Rb-tracer injection which followed 3–5 min after the completion of dipyridamole
infusion. PET images were analyzed semi-automatically using Cedars-Sinai Cardiac Suite QPS/QGS®
(Cedars-Sinai Medical Center, Los Angeles, CA, USA) for Syngo.Via (Siemens, Knoxville, TN, USA).
The accuracy of slice-alignments in the ventricle was assessed by planes and intervened if necessary.
Perfusion defects were subsequently quantified in the total left ventricle myocardium. The magnitude
of the rest perfusion defects was determined automatically by comparing the polar plot of a minipig to
that of the human normal database on a pixel-by-pixel basis. A 2.5 standard deviation cut-off was used
to define whether a pixel count fell below a normal value. Mean Standardized Uptake Values were
measured in the infarcted area (SUVmean,infarct) as well as the non-infarcted myocardium including
blood pool (SUVmean,background) and the ratio between the two (SUVindex) was calculated.
During the examination heart rate was measured continuously and non-invasive blood pressure
was measured every minute. The hemodynamic response to dipyridamole was evaluated by
calculating Rate-Pressure-Products (RPP) at rest and stress as the product of non-invasive systolic
blood pressure and heart rate at rest and stress, respectively.
2.6. Histology
After euthanasia, the heart of the minipig was removed and the infarct area was located together
with the suture. The heart was cut into 1.5 cm thick short axis slices, and 4 areas from the slice below
the ligation were selected for histology. The four areas were: (1) Infarct area; (2) Peri-infarct area;
(3) Peri-infarct area at the side of injections; and (4) Remote myocardium, beyond the peri-infarct area.
The tissue was fixed in 4% paraformaldehyde and embedded in paraffin. Slices of 5 µm thickness
were cut for staining at four different levels in each tissue sample. Antigen retrieval was performed
before all stainings. The tissue was stained for collagen by Masson’s Trichrome (Hospital Pharmacy,
Rigshospitalet), tissue organization and inflammation by hematoxylin and eosin (H&E) (Hospital
Pharmacy, Rigshospitalet), macrophages by CD68 (Agilent Technologies, Glostrup, Denmark, 1:100),
myofibroblasts by α-smooth muscle actin (α-SMA) (Agilent Technologies), CD31 (Bio-Rad Laboratories,
Copenhagen, Denmark, 1:50), and integrin αvβ3 (Merck Millipore, Darmstadt, Germany, 1:75).
Visualization was performed used Carl Zeiss Axio Imager Z.1 microscope and Axiovision 4.6.3 software.
Mason’s Trichrome was analyzed by three random areas at×1.25 magnification for each slice, resulting
in a total of 12 random fields for each heart area from each minipig. The percentage of collagen
staining compared to the whole image was analyzed using Image J software (Fiji). A similar number
of fields were acquired for each staining. The level of inflammation was assessed by scoring each
×5 magnification field from 0 to 3, ranging from 0 = no visible inflammation, 1 = <10% inflammatory
cells, 2 = 10–50% inflammatory cells, and 3 = >50% inflammatory cells of total cells. High power fields
of ×20 magnification were used for total manual CD68 count. Similarly, the same magnification was
used for α-SMA fibroblast percentage measurements in the scar area, and CD31 and integrin αvβ3.
All manual assessment was performed by two independent observers.
2.7. Statistical Analysis
Categorical variables were expressed as percentages and continuous variables were reported as
means and standard deviations. Differences in continuous variables between groups were assessed
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with students t-test while differences in groups over time were assessed with paired t-test. A general
linear model was used to analyse data with more than one time-point and the resulting regression lines
were compared for differences between groups. A two tailed p-value < 0.05 was considered statistically
significant. Statistical analyses were performed using SAS® for Windows, version 9.1 (SAS institute,
Cary, NC, USA).
3. Results
3.1. 82Rubidium PET before Myocardial Infarction
Before induction of myocardial infarction all minipigs showed a homogenic distribution of
82Rb in both rest and stress 82Rb PET images and no RGD uptake was noted. During stress,
RPP doubled from about 5000 at rest to about 10,000 mmHg/min, mainly due to increased heart
rate. Mean CFR was 2.80 (±1.17) for non-pASC-treated minipigs and 2.25 (±0.43) for pASC-treated
minipigs. Mean ejection fractions (EF) were 80 (±4)% and 92 (±2)% during rest and 87 (±8)% and
91 (±1)% during dipyridamole stress in non-pASC and pASC-treated minipigs (Table 1).
Table 1. Left ventricle function parameters and perfusion before and after induction of a myocardial
infarction in pASC and non-pASC-treated minipigs measured by 82Rb PET-CT.
Non-pASC Treatment pASC Treatment
Baseline
(n = 2)
1 Week Post-MI
(n = 2)
4 Weeks
Post-MI (n = 2) p-Value
Baseline
(n = 3)
1 Week Post-MI
(n = 3)
4 Weeks
Post-MI (n = 2) p-Value
Rest flow (mL/g/min) 0.73 (±0.19) 0.92 (±0.08) 0.70 (±0.16) NS 0.94 (±0.19) 1.02 (±0.58) 1.38 (±0.76) NS
Rest EDV (mL) 30 (±3) 26 (±4) 31 (±6) NS 25 (±3) 35 (±8) 39 (±6) 0.06
Rest ESV (mL) 6 (±1) 5 (±1) 6 (±3) NS 2 (±0) 6 (±3) 6 (±2) NS
Rest EF (%) 80 (±4) 84 (±1) 81 (±5) NS 92 (±2) 84 (±4) 85 (±8) NS
Stress flow (mL/g/min) 1.80 (±0.20) 1.61 (±0.08) 1.30 (±0.16) <0.05 2.07 (±0.23) 1.80 (±0.42) 2.05 (±0.36) NS
Stress EDV (mL) 29 (±4) 25 (±1) 26 * NS 20 (±2) 27 (±7) 33 (±1) <0.03
Stress ESV (mL) 4 (±2) 5 (±1) 3 * NS 2 (±1) 5 (±1) 4 (±1) NS
Stress EF (%) 87 (±8) 83 (±2) 89 * NS 91 (±3) 82 (±1) 89 (±3) NS
CFR 2.80 (±1.17) 1.79 (±0.26) 1.95 (±0.29) NS 2.25 (±0.43) 2.10 (±0.96) 1.68 (±0.67) NS
Abbreviations: pASC: porcine adipose-derived mesenchymal stromal cell; EDV: End-diastolic-volume; ESV:
End-systolic-volume; EF: Ejection fraction; CFR: Coronary flow reserve; MI: Myocardial infarction. *: Only one
measurement was possible, due to ECG trigger problems; NS: Non-significant.
3.2. 82Rubidium PET after Myocardial Infarction
One week and one month after myocardial infarction, four of the five minipigs
(two stem-cell-treated and two non-stem-cell-treated) showed a myocardial perfusion defect located to
the anterior ventricle myocardium (Figure 2). One minipig, with confirmed myocardial infarction after
one week, died before the planned one-month post infarction scan. Characteristics in pASC-treated
and saline-treated minipigs at baseline, one week and one month following myocardial infarction
are provided in Table 1. Myocardial stress flows were significantly lower at follow-up compared to
baseline in non-pASC-treated minipigs (1.80 (±0.20) mL/g/min vs. 1.30 (±0.16) mL/g/min, p < 0.05),
something that was not noted in pASC-treated minipigs. Even though, there was no difference in
the decrease of stress flow or coronary flow reserve from baseline to follow-up between non-pASC
vs. pASC-treated minipigs when comparing regression lines. In pASC-treated minipigs end diastolic
volumes (EDV) tended to be higher at follow-up compared to baseline at rest (25 (±3) mL vs. 39 (±6)
mL, p = 0.06) and were significantly higher at stress (20 (±2) mL vs. 33 (±1) mL, p < 0.05), something
that was not observed in non-pASC-treated minipigs (Table 1). Left ventricular ejection fractions
(LVEF), on the other hand, did not change from baseline to follow-up in either non-pASC-treated
(80 (±4)% vs. 81 (±5)% at rest, and 87 (±8)% vs. 89% at stress) or pASC-treated minipigs (92 (±2)%
vs. 85 (±8)% at rest, and 81 (±3)% vs. 89 (±3)% at stress) (Table 1).
Diagnostics 2018, 8, 33 7 of 12
Diagnostics 2018, 8, x FOR PEER REVIEW  7 of 12 
 
 
Figure 2. Modified from [12]. RGD (Top) and 82Rb stress (Bottom) PET at baseline, one week and one 
month after induced myocardial infarction. (A) Myocardial infarction; (B) Sternotomy. 
3.3. 68NODAGA-RGD PET after Myocardial Infarction 
All minipigs showing myocardial perfusion defects in the 82Rb PET images also showed RGD 
uptake in the infarcted myocardium one week and one month after myocardial infarction regardless 
of pASC treatment or not (Figure 1). SUVmean in the infarcted myocardium was significantly higher 
than the background SUVmean (non-infarcted myocardium including blood pool) after both one week 
and one month (p < 0.05 for both). Mean SUVmean in the RGD uptaking myocardium in pASC-treated 
minipigs was 1.23 (±0.40) and 1.02 one week and one month after infarction while SUVmean was 1.44 
(±0.13) and 1.26 (±0.01) in saline-treated minipigs (non-significant). The index between SUV in the 
infarcted and background (SUVindex) was 1.37 (±0.22) and 1.19 one week and one month after 
infarction in pASC-treated minipigs (p-value could not be calculated because only one minipig was 
alive at the last scan) and 1.34 (±0.05) and 1.22 (±0.06) for saline-treated minipigs (p < 0.05) (Table 2). 
Thus, SUVindex in saline-treated minipigs one month after infarction were significantly lower than 
SUVindex one week after infarction. There was no difference in SUVindex between pASC-treated vs 
saline-treated minipigs after one week, whereas groups could not be compared for differences after 
one month due to only one pASC-treated minipig left with confirmed myocardial infarction. 
Table 2. (A) RGD uptake in non-pASC-treated minipigs with myocardial infarction. (B) RGD uptake 
in pASC-treated minipigs with myocardial infarction. 
 
One Week Post 
Infarction 
Four Weeks Post 
Infarction p-Value 
(A) non-pASC-treated minipigs 
SUVMean,infarct 1.44 (±0.13) 1.26 (±0.01) NS 
SUVMean,background 1.07 (±0.06) 1.04 (±0.06) NS 
SUVindex 1.34 (±0.05) 1.22 (±0.06) <0.05 
(B) pASC-treated minipigs 
SUVMean,infarct 1.23 (±0.40) 1.02 * - 
SUVMean,background 0.88 (±0.16) 0.86 * - 
SUVindex 1.37 (±0.22) 1.19 * - 
Figure 2. Modified from [12]. RGD (Top) and 82 t ( tto ) PET at baseline, one week and one
month after induced myocardial infarction. ( ) ti ; (B) Sternotomy.
3.3. 68NODAGA-RGD PET after yocardial Infarction
All minipigs showing myocardial perfusion defects in the 82Rb PET images also showed RGD
uptake in the infarcted myocardium one week and one month after myocardial infarction regardless
of pASC treatment or not (Figure 1). SUVmean in the infarcted myocardium was significantly higher
than the background SUVmean (non-infarcted myocardium including blood pool) after both one week
and one month (p < 0.05 for both). Mean SUVmean in the RGD uptaking myocardium in pASC-treated
minipigs was 1.23 (±0.40) and 1.02 one week and one month after infarction while SUVmean was
1.44 (±0.13) and 1.26 (±0.01) in saline-treated minipigs (non-significant). The index between SUV
in the infarcted and background (SUVindex) was 1.37 (±0.22) and 1.19 one week and one month
after infarction in pASC-treated minipigs (p-value could not be calculated because only one minipig
was alive at the last scan) and 1.34 (±0.05) and 1.22 (±0.06) for saline-treated minipigs (p < 0.05)
(Table 2). Thus, SUVindex in saline-treated minipigs one month after infarction were significantly lower
than SUVindex one week after infarction. T ere was no difference in SUVindex between pASC-treated
vs. saline-treated minipigs after one week, whereas groups could not be compared for differences after
one month due to only one pASC-treated minipig left with confirmed myocardial infarction.
Table 2. (A) RGD uptake in non-pASC-tre ted minipigs with myocardial infarction. (B) RGD uptake
in pASC-treated minipigs with myocardial infarction.
One Week Post Infarction Four Weeks Post Infarction p-Value
(A) non-pASC-treated minipigs
SUVMean,infarct .44 (±0.13) 1.26 (±0.01) NS
SUVMean,background 1.07 (±0.06) 1.04 (±0.06) NS
SUVindex 1.34 (±0.05) 1.22 (±0.06) <0.05
(B) pASC-treated minipigs
SUVMean,infarct 1.23 (±0.40) 1.02 * -
SUVMean,background 0.88 (±0.16) 0.86 * -
SUVindex 1.37 (±0.22) 1.19 * -
Abbreviations: pASC: porcine adipose-derived mesenchymal stromal cell; SUVMean,infarct: Standardized Uptake
Value in infarcted myocardium; SUVMean,background: Standardized Uptake Value in non-infarcted myocardium
including blood pool; SUVindex: (Standardized Uptake Value in infarcted myocardium)/(Standardized Uptake
Value in non-infarcted myocardium including blood pool). *: Only one minipig with proven MI.
Diagnostics 2018, 8, 33 8 of 12
3.4. Histological Findings
During dissection, a small but clearly infarcted area was visible in all minipigs except one,
confirming the 82Rb perfusion imaging. For comparison purposes, the minipig that died prematurely
was also included in the histology analysis. Integrin αvβ3 was identified mainly in the infarcted
area, and expression was co-localized with CD31 on adjacent slices (Figure 3). No difference in CD31
positive vessel density was observed between the groups. Similarly, no difference was observed
between the level of inflammation and CD68 positive cells. There was a tendency of increased collagen
tissue and scar area occupied by α-SMA positive myofibroblasts in the pASC group.
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Figure 3. Myocardial histology. (A) Representative image of histology sampling from infarcted
areas (B,C,E); peri-infarcted areas (D,F,G); (B) Masson’s Trichrome ×1.25 (C) Hematoxylin-eosin ×5
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co-localization of integrin αvβ3 and CD31.
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in species or infarct size and whether the different conclusions rely on our relatively small sample size
remains unsettled.
In another study angiogenesis after myocardial infarction by ligation of LAD in Spraque–Dawley
rats using [68Ga]DOTA-E-[c(RGDfK)]2 PET was examined [16]. The infarcted myocardium showed
higher tracer uptake than the remote myocardium 7 days and 4 weeks post-infarct (infarct/remote
myocardium ratio 2.25 (±0.14) and 2.13 (±0.37)). Compared to sham-operated-rats both infarcted
and remote myocardium showed higher tracer uptake 7 days and 4 weeks postinfarct where it
coincided with increased interstitial fibrosis. Again, whether the higher infarct/remote myocardium
ratio compared to the ones measured in our study relies on tracer difference, species or infarct size
remains unknown.
The primary outcomes for most clinical trials investigating the effect of cellular therapy are LVEF,
EDV or end-systolic volume (ESV) measured by MRI, echocardiography, and/or CT. These are fine as
surrogate endpoints for phase I/II clinical trials but do not relate directly to the mechanisms by which
the cells exert their regenerative effect. The addition of other endpoints might clarify the effect of cell
therapy [17,18].
Angiogenesis is a vital part of the reparative process following myocardial infarction. It is also
thought to be one of the main mechanisms behind the regenerative effect of cardiac cellular therapy
and is in pre-clinical studies traditionally assessed in histology by counting of vessel density in
affected areas of the heart [19–21]. Since this is not feasible in clinical studies, clinical trials with
thorough functional design do not usually investigate angiogenesis due to lack of methods [22].
While angiogenesis is associated with post-infarct remodeling of the left ventricle, stratification of
patients with RGD-PET following myocardial infarction may prove effective [2]. Although strictly
hypothetical, one would assume a patient with RGD uptake to have a better prognosis than a patient
not taking up RGD in a myocardial infarction of a similar size. Furthermore, the “clearance”
of RGD at follow-up PET might be of importance. Indicative of the latter, although limited to
two myocardial infarction patients, was a study by Luo et al. [23]. Both patients showed retention
of 68Ga-BNOTA-PRGD2 in the infarcted region of the myocardium 1 week after the cardiac event.
At follow-up, retention of 68Ga-BNOTA-PRGD2 remained in the infarcted myocardium of the
still symptomatic patient whereas no uptake could be visualized in the asymptomatic patient.
Further studies are required to clarify the association between RGD uptake and post-infarct prognosis.
Moreover, the most favorable time point for investigation of RGD uptake post infarct remains unsettled.
Interpretation of RGD uptake is not limited to ischemic heart disease; post-stroke repair processes
after ischemic injury are subject to neurovascular research. Tumor angiogenesis has been well
recognized as an essential hall mark of tumor growth, invasion and metastasis and, therefore,
RGD PET can be used for tumor detection and staging in different types of cancer to provide additional
information to existing imaging modalities [24,25]. A number of other RGD peptide PET tracers have
been clinically investigated including 18F-Galacto-RGD, 18F-Fluciclatide, 18F-RGD-K5, 18F-FPPRGD2,
18F-Alfatide, 68Ga-NOTA-RGD and 68Ga-NOTA-PRGD2 [25]. The detection efficiency of lesions in
different regions is highly dependent on the difference in in vivo biodistribution patterns of each single
RGD peptide.
5. Limitations
Our relatively small number of animals in each group was a limitation, together with the relatively
small myocardial infarctions. Another limitation was that the specificity of RGD was not studied
by a non-targeted control tracer or blocking experiments. As a result, we were limited to conclude
that (1) RGD uptake was located specifically to the myocardial infarct area; (2) histologically, integrin
αvβ3 was only found in the infarct area and not in remote areas; (3) histologically, integrin αvβ3 was
co-localized with CD31. In summary, the increased RGD uptake in the myocardial infarct area was
a strong indicator of angiogenesis.
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6. Conclusions
Myocardial infarctions were verified by 82Rb dipyridamole stress PET. Indications of angiogenesis
in the myocardial infarct area were documented by increased RGD uptake located specifically to the
MI area in RGD-PET which, in addition, was the only area that histologically showed presence of
integrin αvβ3 co-localized with CD31. However, no differences between pASC-treated minipigs and
non-pASC-treated minipigs could be shown.
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